蔓迪国际冲击“防脱第一股” 千亿赛道存高增长隐忧

Core Insights - The "bald economy" sector is gaining attention as Mandi Inc., a subsidiary of Sihuan Pharmaceutical, has submitted its IPO application to list on the Hong Kong Stock Exchange, aiming to become the first publicly listed company in China's hair health sector [2] - Mandi Inc. is backed by a rigid demand from over 339 million people suffering from hair loss and a market projected to grow at a compound annual growth rate (CAGR) of 11.3%, reaching a market size of 171.4 billion yuan by 2035 [3][4] - Despite strong performance and market potential, Mandi Inc. faces challenges such as over-reliance on core products, insufficient R&D investment, and high supply chain concentration [6][7] Market Dynamics - The hair health market in China is experiencing explosive growth, with the number of hair loss sufferers expected to reach 339 million by 2024, predominantly among individuals under 35 years old [3] - The market for hair health management is projected to exceed 80 billion yuan in 2024, with a sustained CAGR of 11.3% from 2024 to 2035 [3] - Mandi Inc. has established a strong competitive position, with its core product line, including the Mandi® series, holding over 70% market share in the hair loss treatment sector [4] Financial Performance - Mandi Inc.'s revenue grew from 982 million yuan in 2022 to 1.455 billion yuan in 2024, with net profit increasing from 202 million yuan to 390 million yuan during the same period, reflecting a CAGR of 21.7% [4][5] - The gross profit margin has remained stable above 80%, reaching 82.7% in 2024, significantly higher than the industry average [4] Challenges and Risks - Mandi Inc. heavily relies on its core product line, with 92.4% of its revenue in the first half of 2025 coming from the Mandi series, indicating vulnerability to market changes [6][7] - The company has low R&D investment, with only 2.62% of revenue allocated to R&D in the first half of 2025, raising concerns about long-term competitiveness [7] - High concentration in the supply chain, with the top five suppliers accounting for 75.6% of procurement, poses risks to production stability and cost control [7] Strategic Plans - Mandi Inc. plans to use IPO proceeds to enhance R&D, expand its product pipeline, and optimize its supply chain, focusing on female hair loss treatments and new topical formulations [8] - The company aims to balance sales and R&D investments to build long-term technological barriers while accelerating new product iterations to reduce dependence on the Mandi series [8] - The competitive landscape is shifting towards technology and brand competition, necessitating Mandi Inc. to maintain its market share amidst increasing competition from traditional pharmaceutical companies and emerging brands [8][9]